Gyre Therapeutics, Inc. Accumulated Other Comprehensive Income
Gyre Therapeutics, Inc. (GYRE) had Accumulated Other Comprehensive Income of $1.49 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-07
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.49M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $586.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$908.00K; Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed -$779.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.70M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | $1.49M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $586.00K 10-Q · filed 2026-05-08 | |
| 2025-12-31 | -$908.00K 10-Q · filed 2026-08-07 | -$779.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | -$1.70M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | -$2.29M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$2.49M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | -$2.60M 10-K · filed 2026-03-13 | |
| 2024-09-30 | -$946.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$2.01M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$1.74M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$1.64M 10-K · filed 2025-03-17 | |
| 2022-12-31 | -$392.00K 10-K · filed 2024-03-27 | |
| 2021-09-30 | $1.00K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $2.00K 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $5.00K 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $5.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $8.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $41.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $140.00K 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $34.00K 10-K · filed 2021-03-04 | |
| 2019-09-30 | $31.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $57.00K 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $13.00K 10-Q · filed 2019-05-02 | |
| 2018-12-31 | -$4.00K 10-K · filed 2020-02-20 | |
| 2018-09-30 | -$24.00K 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $4.00K 10-Q · filed 2018-08-02 | |
| 2018-03-31 | -$4.00K 10-Q · filed 2018-05-03 | |
| 2017-09-30 | $4.00K 10-Q · filed 2017-11-02 | |
| 2016-12-31 | -$1.00K 10-K · filed 2018-03-19 | |
| 2016-09-30 | $4.00K 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $7.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $4.00K 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $1.00K 10-K · filed 2017-03-08 | |
| 2015-09-30 | $16.00K 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $11.00K 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $23.00K 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $4.00K 10-Q · filed 2015-07-31 | |
| 2014-09-30 | $55.00K 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $110.00K 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $66.00K 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $87.00K 10-K · filed 2015-03-16 | |
| 2013-09-30 | $95.00K 10-Q · filed 2013-11-06 | |
| 2013-06-30 | -$14.00K 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $188.00K 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $201.00K 10-K · filed 2014-03-14 | |
| 2012-09-30 | $377.00K 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $194.00K 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $227.00K 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $36.00K 10-K · filed 2013-03-15 | |
| 2011-09-30 | -$19.00K 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $199.00K 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $225.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |